Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Nicole Paulk
AddedFeb 15, 2024
UpdatedMay 31, 2026
Nicole Paulk

Nicole Paulk

Board Member, GRO Biosciences

LinkedInThe Org

Nicole Paulk's Career

GRO Biosciences
GRO Biosciences

Boston, MA, US

Board Member· Board
Excision BioTherapeutics
Excision BioTherapeutics

Philadelphia, PA, US

Board Member· Board
Dyno Therapeutics
Dyno Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Nicole Paulk's Career

GRO Biosciences
GRO Biosciences
Series A$32.3M442016Boston, MA, US
Board Member· Board

Leadership at GRO Biosciences

Rakhshita DharRakhshita DharBoard Member
Bruce BeutelBruce BeutelBoard Member
Ross ThyerRoss ThyerCo-Founder
Christopher RobertsChristopher RobertsBoard Member
Christopher GreggChristopher GreggCo-Founder
Daniel J MandellDaniel J MandellCo-Founder

Similar to GRO Biosciences

Grove BiopharmaGrove BiopharmaChicago, IL, USBiotherapeuticsest. 2020Grove BiopharmaChicago, IL, US · est. 2020

Grove: A preclinical biotech startup innovating biotherapeutics for unmet medical needs.

Seed · $10.5M8
Groove BiopharmaGroove BiopharmaSeattle, WA, USDrugs, Therapeuticsest. 2008Groove BiopharmaSeattle, WA, US · est. 2008

Groove Biopharma: Pioneering microRNA therapeutics for cancer, fibrosis, and infectious diseases.

Series B · $9.9M6
AI ProteinsAI ProteinsBoston, MA, USProtein Therapeuticsest. 2021AI ProteinsBoston, MA, US · est. 2021

AI Proteins: A biotech firm specializing in the design and engineering of synthetic mini protein therapeutics.

Series B · $18.2M44
ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35
Excision BioTherapeutics
Excision BioTherapeutics
Series A$77.6M512015Philadelphia, PA, US
Board Member· Board

Leadership at Excision BioTherapeutics

Vasudev BaileyVasudev BaileyBoard Member
William CarsonWilliam CarsonBoard Member
Tom MalcolmTom MalcolmCo-Founder
Daniel DornbuschDaniel DornbuschBoard Member
Ashok KrishnamurthiAshok KrishnamurthiBoard Member
Kamel KhaliliKamel KhaliliCo-Founder

Similar to Excision BioTherapeutics

TherabiolTherabiolSan Francisco, CA, USImmune Therapiesest. 2012TherabiolSan Francisco, CA, US · est. 2012

Therabiol, Inc.: A San Francisco-based biotech firm specializing in developing immune therapies for viral infections.

Seed · $150k5
ExcepgenExcepgenSan Francisco, CA, USGene Therapies, Vaccinesest. 2018ExcepgenSan Francisco, CA, US · est. 2018

ExcepGen: A San Francisco-based biotech firm innovating in drug discovery for next-gen therapeutics.

Seed · $4.2M6
Exegenesis BioExegenesis BioLansdale, PA, USGene Therapyest. 2019Exegenesis BioLansdale, PA, US · est. 2019

Exegenesis: A global leader in gene therapy, innovating new medicines for China and worldwide.

Series B · $10M17
RegenxbioRegenxbioRockville, MD, USGene Therapyest. 2008RegenxbioRockville, MD, US · est. 2008

REGENXBIO Inc., a global biotech firm, specializes in developing and commercializing gene therapy solutions.

Public · $638.2M401
Dyno Therapeutics
Dyno Therapeutics
Series A$109M1332018Cambridge, MA, US
Board Member· Board

Leadership at Dyno Therapeutics

Tomas BjorklundTomas BjorklundCo-Founder
George ChurchGeorge ChurchCo-Founder
Jorge CondeJorge CondeBoard Member
Eric KelsicEric KelsicCo-Founder
Alan CraneAlan CraneBoard Member
Adrian VeresAdrian VeresCo-Founder

Similar to Dyno Therapeutics

Apertura Gene TherapyApertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29
AavogenAavogenRockville, MD, USGene Therapeuticsest. 2015AavogenRockville, MD, US · est. 2015

US-based AAVogen, a biotech startup, innovates gene therapeutics for muscle wasting diseases.

Seed · $4.7M5
Affinia TherapeuticsAffinia TherapeuticsWaltham, MA, USGene Therapiesest. 2019Affinia TherapeuticsWaltham, MA, US · est. 2019

Affinia Therapeutics: A biotech firm innovating gene therapies for muscle and CNS diseases.

Series B · $170M75
Capsida BiotherapeuticsCapsida BiotherapeuticsBuena Park, CA, USGene Therapyest. 2019Capsida BiotherapeuticsBuena Park, CA, US · est. 2019

Capsida: A US-based biotech firm specializing in monogenetic and sporadic CNS/non-CNS disorders.

Late Stage Private · $140M132

Nicole Paulk's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Nicole Paulk

Andrew EllingtonAndrew EllingtonCo-Founder · GRO BiosciencesNamasivayam AmbalavananNamasivayam AmbalavananBoard Member · ResBioticNicholas PashosNicholas PashosFounder · BioAestheticsNewton HowardNewton HowardBoard Member · ni2oChristos AlexakosChristos AlexakosCo-Founder · InSyBioCharles GawadCharles GawadBoard Member · BioSkryb Genomics